This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rezkalla, S. Articles by Khatib, R. Search for Related Content PubMed PubMed Citation Articles by Rezkalla, S. Articles by Khatib, R.

Circulation, Vol 81, 1039-1046, Copyright © 1990 by American Heart Association

ARTICLES

Beneficial effects of captopril in acute coxsackievirus B3 murine myocarditis

S Rezkalla, RA Kloner, G Khatib and R Khatib
Department of Medicine, Harper Hospital, Detroit, Michigan.

To date, there is no universally accepted therapy for viral myocarditis. We investigated the effect of the angiotensin converting enzyme inhibitor captopril on both early and late phases of coxsackievirus murine myocarditis. Mice were infected with coxsackievirus B3 and were divided into two main protocols. Mice in the early treatment protocol (n = 30) were treated on day 1 after infection with either captopril or saline through day 6 of infection and euthanized on day 6 of infection. In the late treatment protocol, mice (n = 60) were treated starting on day 10 of infection through day 30 of infection with either captopril or saline. Mice were killed on days 20 and 30 of infection. In the early treatment protocol, heart weight was 67 +/- 14 mg in the captopril-treated group versus 98 +/- 17 mg in the control group (p less than 0.0001). The degree of inflammation, necrosis, and dystrophic calcification assessed with a semiquantitative histological score was significantly less in the captopril-treated group. The degree of pathological involvement determined by planimetry of histological sections was 8.1 +/- 7.2% for the captopril-treated group versus 22.5 +/- 10.0% for the saline-treated group (p less than 0.0001). In the late treatment protocol, captopril also caused a reduction in heart weight as compared with controls at day 20 (116 +/- 21 mg in captopril-treated group vs. 166 +/- 34 mg in controls, p less than 0.0001) and also at day 30 (136 +/- 23 mg in captopril-treated group vs. 185 +/- 48 mg in controls, p less than 0.004). On days 20 and 30 of infection, the degree of inflammation, necrosis, and dystrophic calcification was similar in both groups. We conclude that captopril is beneficial in acute coxsackievirus B3 murine myocarditis because it reduces heart weight and necrosis when administered early and reduces heart weight when administered in a delayed manner.

This article has been cited by other articles:

				P. G. Arndt, S. K. Young, K. R. Poch, J. A. Nick, S. Falk, R. W. Schrier, and G. S. Worthen Systemic Inhibition of the Angiotensin-Converting Enzyme Limits Lipopolysaccharide-Induced Lung Neutrophil Recruitment through Both Bradykinin and Angiotensin II-Regulated Pathways J. Immunol., November 15, 2006; 177(10): 7233 - 7241. [Abstract] [Full Text] [PDF]

				C. S. Carter, G. Onder, S. B. Kritchevsky, and M. Pahor Angiotensin-Converting Enzyme Inhibition Intervention in Elderly Persons: Effects on Body Composition and Physical Performance J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2005; 60(11): 1437 - 1446. [Abstract] [Full Text] [PDF]

				K. Yamamoto, T. Shioi, K. Uchiyama, T. Miyamoto, S. Sasayama, and A. Matsumori Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-kappa B activation in knockout mice J. Am. Coll. Cardiol., December 3, 2003; 42(11): 2000 - 2006. [Abstract] [Full Text] [PDF]

				L. M. Godsel, J. S. Leon, K. Wang, J. L. Fornek, A. Molteni, and D. M. Engman Captopril Prevents Experimental Autoimmune Myocarditis J. Immunol., July 1, 2003; 171(1): 346 - 352. [Abstract] [Full Text] [PDF]

				J. S. Leon, K. Wang, and D. M. Engman Captopril Ameliorates Myocarditis in Acute Experimental Chagas Disease Circulation, May 6, 2003; 107(17): 2264 - 2269. [Abstract] [Full Text] [PDF]

				M. Miyoshi, K. Nagata, T. Imoto, O. Goto, A. Ishida, and T. Watanabe ANG II is involved in the LPS-induced production of proinflammatory cytokines in dehydrated rats Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2003; 284(4): R1092 - R1097. [Abstract] [Full Text] [PDF]

				T. Watanabe, M. Hashimoto, M. Wada, T. Imoto, M. Miyoshi, D. Sadamitsu, and T. Maekawa Angiotensin-converting enzyme inhibitor inhibits dehydration-enhanced fever induced by endotoxin in rats Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2000; 279(4): R1512 - R1516. [Abstract] [Full Text] [PDF]

				N. M. Rowe, P. Impellizzeri, M. Vaynblat, N. M. Lawson, Y. D. Kim, M. Sierra, P. Homel, A. J. Acinapura, J. N. Cunningham Jr, and J. H. Burack STUDIES IN THORACIC AORTIC GRAFT INFECTIONS: THE DEVELOPMENT OF A PORCINE MODEL AND A COMPARISON OF COLLAGEN-IMPREGNATED DACRON GRAFTS AND CRYOPRESERVED ALLOGRAFTS J. Thorac. Cardiovasc. Surg., November 1, 1999; 118(5): 857 - 865. [Abstract] [Full Text] [PDF]

				C. Kawai From Myocarditis to Cardiomyopathy: Mechanisms of Inflammation and Cell Death : Learning From the Past for the Future Circulation, March 2, 1999; 99(8): 1091 - 1100. [Abstract] [Full Text] [PDF]

				M. P. Reyes, R. Khatib, G. Khatib, K.L. Ho, F. Smith, and R. A. Kloner Prolonged Captopril Therapy in Murine Viral Myocarditis Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(1): 43 - 49. [Abstract] [PDF]

				H. Takada, C. Kishimoto, and Y. Hiraoka Therapy With Immunoglobulin Suppresses Myocarditis in a Murine Coxsackievirus B3 Model : Antiviral and Anti-inflammatory Effects Circulation, September 15, 1995; 92(6): 1604 - 1611. [Abstract] [Full Text]